Virchows Archiv

, Volume 464, Issue 2, pp 221–228 | Cite as

Fatty acid synthase overexpression in adult testicular germ cell tumors: potential role in the progression of non-seminomatous germ cell tumors

  • Kosuke Miyai
  • Keiichi Iwaya
  • Tomohiko Asano
  • Seiichi Tamai
  • Osamu Matsubara
  • Hitoshi Tsuda
Original Article
First Online:
Received:
Revised:
Accepted:

Abstract

Overexpression of fatty acid synthase (FASN), which is a key enzyme responsible for the endogenous synthesis of fatty acids, and its association with multistep progression have been demonstrated in various human malignant tumors. We aimed to clarify the potential role of FASN overexpression in the development and progression of adult testicular germ cell tumors (TGCTs). From the primary sites of a cohort of 113 TGCT cases, we obtained 221 histological components: 53 intratubular germ cell neoplasias, unclassified (IGCNUs), 84 seminomas, 32 embryonal carcinomas, seven choriocarcinomas, 21 yolk sac tumors, and 24 teratomas. Samples were analyzed for overexpression of FASN by immunohistochemistry. Intensities of immunoreactivity and the fraction of positive cells were classified into each four categories (intensity, 0 to 3; fraction, 0–10 % = 1, 11–50 % = 2, 51–80 % = 3, and >80 % = 4). The overall score was determined by multiplication of both scores and overall scores greater than 6 were considered FASN overexpression. On a component basis, FASN overexpression was detected in 8 % of seminomas but not in IGCNUs (0 %) and was detected frequently in non-seminomatous germ cell tumors (NSGCTs) (88 % of embryonal carcinomas, all choriocarcinomas, 81 % of yolk sac tumors, and 54 % of teratomas). There were no cases of a mixed tumor (i.e., a tumor with multiple histological components) that overexpressed FASN in seminoma components but not in co-existing NSGCT components, suggesting sequential progression. Our immunohistochemical data suggest that FASN overexpression occurs as a late event during the progression from IGCNUs/seminomas to NSGCTs.

Keywords

Testis Germ cell tumor Fatty acid synthase Immunohistochemistry 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was supported in part by a grant-in-aid for Promotion of Defence Medicine from the Ministry of Defense, Japan (KI, HT, OM), and by a grant-in-aid for cancer research from the Ministry of Health, Labor, and Welfare, Japan (HT, KI).

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Alo PL, Galati GM, Sebastiani V, Ricci F, Visca P, Mariani L, Romagnoli F, Lombardi G, Tondo UD (2005) Fatty acid synthase expression in Paget’s disease of the vulva. Int J Gynecol Pathol 24:404–408PubMedCrossRefGoogle Scholar
  2. 2.
    Bosl GJ, Motzer RJ (1997) Medical progress: testicular germ-cell cancer. N Engl J Med 337:242–253PubMedCrossRefGoogle Scholar
  3. 3.
    Cheng L, Zhang S, Eble JN, Beck SD, Foster RS, Wang M, Ulbright TM (2012) Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. Mod Pathol 25:1432–1438PubMedCrossRefGoogle Scholar
  4. 4.
    Diraison F, Yankah V, Letexier D, Dusserre E, Jones P, Beylot M (2003) Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans. J Lipid Res 44:846–853PubMedCrossRefGoogle Scholar
  5. 5.
    Ghavamnasiri MR, Saeedi Saedi H, Shahid Sales S, Ghafarzadegan K (2010) Clinical relevance of HER-2/neu overexpression in patients with testicular nonseminomatous germ cell tumor. Urol J 7:26–29PubMedGoogle Scholar
  6. 6.
    Gopalan A, Dhall D, Olgac S, Fine SW, Korkola JE, Houldsworth J, Chaganti RS, Bosl GJ, Reuter VE, Tickoo SK (2009) Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2, and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol 22:1066–1074PubMedCrossRefGoogle Scholar
  7. 7.
    de Graaff WE, Oosterhuis JW, de Jong B, Dam A, van Putten WL, Castedo SM, Sleijfer DT, Schraffordt Koops H (1992) Ploidy of testicular carcinoma in situ. Lab Invest 66:166–168PubMedGoogle Scholar
  8. 8.
    Heidenreich A (2002) Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue? Curr Opin Urol 12:427–430PubMedCrossRefGoogle Scholar
  9. 9.
    Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP (2000) Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163:1721–1724PubMedCrossRefGoogle Scholar
  10. 10.
    Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M (2008) Fatty acid synthase over expression and poor prognosis in renal cell carcinoma. J Urol 180:1137–1140PubMedCrossRefGoogle Scholar
  11. 11.
    International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603Google Scholar
  12. 12.
    Jacobsen GK, Henriksen OB, von der Maase H (1981) Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer 47:2660–2662PubMedCrossRefGoogle Scholar
  13. 13.
    Kernek KM, Ulbright TM, Zhang S, Billings SD, Cummings OW, Henley JD, Michael H, Brunelli M, Martignoni G, Foster RS, Eble JN, Cheng L (2003) Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol 163:2477–2484PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kollmannsberger C, Nichols C, Bokemeyer C (2006) Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 106:1217–1226PubMedCrossRefGoogle Scholar
  15. 15.
    Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91:6379–6383PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–777PubMedCrossRefGoogle Scholar
  17. 17.
    Menendez JA, Lupu R, Colomer R (2005) Targeting fatty acid synthase: potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. Drug News Perspect 18:375–385PubMedCrossRefGoogle Scholar
  18. 18.
    Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene expression in cancer cells. Proc Natl Acad Sci U S A 101:10715–10720PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101:519–532PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115–2120PubMedGoogle Scholar
  21. 21.
    Miyai K, Yamamoto S, Asano T, Tamai S, Matsubara O, Tsuda H (2010) Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression. Cancer Sci 101:1970–1976PubMedCrossRefGoogle Scholar
  22. 22.
    Miyai K, Yamamoto S, Iwaya K, Asano T, Tamai S, Tsuda H, Matsubara O (2013) Allelotyping analysis suggesting a consecutive progression from intratubular germ cell neoplasm to seminoma and then to embryonal carcinoma of the adult testis. Hum Pathol 44:2312–2322PubMedCrossRefGoogle Scholar
  23. 23.
    Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, Siena SM (2001) Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res 7:2770–2775PubMedGoogle Scholar
  24. 24.
    Woodward PJ, Heidenreich A, Looijenga LHJ, Oosterhuis JW, McLeod DG, Møller H et al (2004) Germ cell tumour. Tumours of the testis and paratesticular tissue. In: Eble JN, Sauter G, Epstein MD (eds) Pathology and genetics of tumours of the urinary system and male genital organs (World Health Organization classification of tumours). IARC Press, Lyon, pp 221–249Google Scholar
  25. 25.
    Netto GJ, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N, Albadine R, Hicks JL, Epstein JI, Yegnasubramanian S, Nelson WG, De Marzo AM (2008) Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol 21:1337–1344PubMedCrossRefGoogle Scholar
  26. 26.
    Oosterhuis JW, Castedo SM, de Jong B, Cornelisse CJ, Dam A, Sleijfer DT, Schraffordt Koops H (1989) Ploidy of primary germ cell tumours of the testis: pathogenetic and clinical relevance. Lab Invest 60:14–20PubMedGoogle Scholar
  27. 27.
    Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF (1998) Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58:4611–4615PubMedGoogle Scholar
  28. 28.
    Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB (2001) Increased fatty acid synthase is a therapeutic target in androgen-independent prostate cancer progression. Prostate 47:102–110PubMedCrossRefGoogle Scholar
  29. 29.
    Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465–6481PubMedGoogle Scholar
  30. 30.
    do Prado RF, da Sliva Machado AL, Colombo CE, Carvalho YR (2011) Immunohistochemical study of the expression if fatty acid synthase and Ki-67 in salivary gland tumors. J Oral Pathol Med 40:467–475PubMedCrossRefGoogle Scholar
  31. 31.
    da Silva SD, Cunha IW, Nishimoto IN, Soares FA, Carraro DM, Kowalski LP, Graner E (2009) Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas. Oral Oncol 45:134–139CrossRefGoogle Scholar
  32. 32.
    Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J (1987) Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 10:19–28PubMedCrossRefGoogle Scholar
  33. 33.
    Sobin LH, Gospodariwicz M, Wittekind C (2009) Urological tumors. Testis. In: Sobin LH, Gospodariwicz M, Wittekind C (ed) TNM classification of malignant tumors. UICC International Union Against Cancer, 7th edn. Willey-Blackwell, New York, pp pp 249–254Google Scholar
  34. 34.
    Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J (2005) Retroperitoneal lymph node dissection in patients with low grade testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174:557–560PubMedCrossRefGoogle Scholar
  35. 35.
    Sugino T, Baba K, Hoshi N, Aikawa K, Yamaguchi O, Suzuki T (2011) Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor if prognosis of cancer patients. Med Mol Morphol 44:146–150PubMedCrossRefGoogle Scholar
  36. 36.
    Swinnen JV, Hemmers H, Deboel L, Foufelle F, Heyuns W, Verhoeven G (2009) Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19:5173–5181CrossRefGoogle Scholar
  37. 37.
    Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19–22PubMedCrossRefGoogle Scholar
  38. 38.
    Van de Sande T, De Schrijver D, Heyns S, Verhoeven G, Swinnen JV (2002) Role of phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642–646PubMedGoogle Scholar
  39. 39.
    Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, Alo P (2004) Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung cancer. Anticancer Res 24:4169–4174PubMedGoogle Scholar
  40. 40.
    Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV, Kuhajda FP (2003) Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 63:7330–7337PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Kosuke Miyai
    • 1
  • Keiichi Iwaya
    • 1
  • Tomohiko Asano
    • 3
  • Seiichi Tamai
    • 2
  • Osamu Matsubara
    • 1
  • Hitoshi Tsuda
    • 1
    • 4
  1. 1.Department of Basic PathologyNational Defense Medical CollegeTokorozawaJapan
  2. 2.Department of Laboratory MedicineNational Defense Medical CollegeTokorozawaJapan
  3. 3.Department of UrologyNational Defense Medical CollegeTokorozawaJapan
  4. 4.Pathology Section, Clinical Laboratory DivisionNational Cancer Centre HospitalTokyoJapan

Personalised recommendations